Moncrieff, J, Kirsch, I. Efficacy of antidepressants in adults. BMJ
2005; 331: 155–7.
Kirsch, I, Deacon, BJ, Huedo-Medina, TB, Scoboria, A, Moore, TJ, Johnson, BT. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med
2008; 2: 45.
Turner, EH, Matthews, AM, Linardatos, E, Tell, RA, Rosenthal, R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med
2008; 358: 252–60.
Fournier, JC, DeRubeis, RJ, Hollon, SD, Dimidjian, S, Amsterdam, JD, Shelton, RC, et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA
2010; 303: 47–53.
Lepola, UM, Loft, H, Reines, EH. Escitalopram (10–20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol
2003; 18: 211–7.
Burke, WJ, Gergel, I, Bose, A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry
2002; 63: 331–6.
Rapaport, MH, Bose, A, Zheng, H. Escitalopram continuation treatment prevents relapse of depressive episodes. J Clin Psychiatry
2004; 65: 44–9.
Alexopoulos, GS, Gordon, J, Zhang, D. A placebo-controlled trial of escitalopram and sertraline in the treatment of major depressive disorder. Neuropsychopharmacology
2004; 29 (suppl): S87.
Khan, A, Leventhal, RM, Khan, SR, Brown, WA. Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration database. J Clin Psychopharmacol
2002; 22: 40–5.
Khan, A, Brodhead, AE, Kolts, RL, Brown, WA. Severity of depressive symptoms and response to antidepressants and placebo in antidepressant trials. J Psychiatr Res
2005; 39: 145–50.
Bech, P, Andersen, H, Wade, A. Effective dose of escitalopram in moderate versus severe DSM-IV major depression. Pharmacopsychiatry
2006; 39: 128–34.
Montgomery, SA, Åsberg, M. A new depression scale designed to be sensitive to change. Br J Psychiatry
1979; 134: 382–9.
Lavori, PW. Clinical trials in psychiatry: should protocol deviation censor patient data?
1992; 6: 39–48; .
Mallinckrodt, CH, Clark, WS, David, SR. Accounting for dropout bias using mixed-effects models. J Biopharm Stat
2001; 11: 9–21.
McLachlan, GJ, Peel, D. Finite Mixture Models. Wiley, 2000.
Zhang, B, Mitchell, SL, Bambauer, KZ, Jones, R, Prigerson, HG. Depressive symptom trajectories and associated risks among bereaved Alzheimer disease caregivers. Am J Geriatr Psychiatry
2008; 16: 145–5.
Larsen, K. Joint analysis of time-to-event and multiple binary indicators of latent classes. Biometrics
2004; 60: 85–92.
Akaike, H. Information theory as an extension of the maximum likelihood principle. In Second International Symposium on Information Theory (eds Petrov, BN, Csaki, F): 267–81. Akademiai Kiado, 1973.
Kasper, S, de Swart, H, Andersen, HF. Escitalopram in the treatment of depressed elderly patients. Am J Geriatr Psychiatry
2005; 13: 884–91.
Thase, ME. Methodology to measure onset of action. J Clin Psychiatry
2001; 62 (suppl 15): 18–21.
Mayer, D. Essential Evidence-based Medicine: 117. Cambridge University Press, 2004.
Kirsch, I, Moore, TJ, Scoboria, A, Nicholls, SS. The emperor's new drugs: an analysis of antidepressant medication data submitted to the US Food and Drug Administration. Prevent Treat
2002; 5: 23.
Uher, R, Muthén, B, Souery, D, Mors, O, Jaracz, J, Placentino, A, et al. Trajectories of change in depression severity during treatment with antidepressants. Psychol Med
2010; 40: 1367–77.
Cohen, J. Statistical Power Analysis for the Behavioural Sciences: 532. Erlbaum, 1988.
Kennedy, SH, Andersen, HF, Thase, ME. Escitalopram in the treatment of major depressive disorder: a meta-analysis. Curr Med Res Opin
2009; 25: 161–75.
Cipriani, A, Furukawa, TA, Salanti, G, Geddes, JR, Higgins, JP, Churchill, R, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet
2009; 373: 746–58.
Box, GEP, Draper, NR. Empirical Model-Building and Response Surfaces: 424. Wiley, 1987.